CGM Use in Islet Transplant Recipients

Subjects who have an Islet Transplantation may have several outcomes including time when
insulin is not required followed in some cases by additional insulin for glucose control as
patients get further away from transplantation. It is unclear what role automated insulin
delivery systems will have in addressing glucose variability in this group of patients who
may have some amount of islet function. As a precursor to understanding ways in which
automated insulin delivery systems may need to be adapted, we propose to gather data on
glucose variability and insulin regimens in individuals who have undergone an islet
transplantation.

Inclusion Criteria:

- Type 1 Diabetes Mellitus

- Recipient of Islet Transplantation

- Age 18 or older

- Females, not currently know to be pregnant

- Demonstration of proper mental status and cognition for the study

- Understanding and willingness to follow the protocol and informed consent form

- Access to the internet and willingness to upload data during the study, including use
of personal laptop

Exclusion Criteria:

- Pregnancy and intent to become pregnant during trial

- Use of acetaminophen (such as Tylenol)

- Current enrollment in another intervention clinical trial that affects glucose
variability